(firstQuint)A 36-Week Extension to Protocol ISA04-03.

 Psoriasis is a chronic skin condition that can have a significant impact on patient's physical and mental well being.

 The most common form of psoriasis is plaque psoriasis.

 Targeted treatments in psoriasis have been reported recently, yet cyclosporine, a calcineurin inhibitor (CNi) remains one of the treatments which has the greatest efficacy.

 Voclosporin represents the possibility of a calcineurin inhibitor which is not only as efficacious as cyclosporine A, but also has an improved toxicity profile.

.

 A 36-Week Extension to Protocol ISA04-03@highlight

The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

